{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunoglobulin", "query": { "intervention": "Immunoglobulin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10425, "total_pages": 1043, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunoglobulin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T15:33:55.674Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04108858", "title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "HER2-Positive Breast Carcinoma", "Metastatic Breast Carcinoma" ], "interventions": [ { "name": "Copanlisib", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-05-20", "completion_date": "2022-04-29", "has_results": true, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-09-02T15:33:55.674Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04108858" }, { "nct_id": "NCT00027443", "title": "Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Myocarditis" ], "interventions": [ { "name": "Muromonab-CD3", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2001-08", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-09-02T15:33:55.674Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027443" }, { "nct_id": "NCT03321643", "title": "Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma", "Richter Syndrome", "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-09-18", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-02T15:33:55.674Z", "location_count": 4, "location_summary": "Duarte, California • La Jolla, California • Sacramento, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03321643" }, { "nct_id": "NCT04551950", "title": "Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "M7824", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2020-10-19", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2024-03-08", "last_synced_at": "2026-09-02T15:33:55.674Z", "location_count": 5, "location_summary": "Stanford, California • Augusta, Georgia • Henderson, Nevada + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551950" }, { "nct_id": "NCT01959490", "title": "Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2013-09-24", "completion_date": "2017-03-29", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-02T15:33:55.674Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01959490" }, { "nct_id": "NCT05577182", "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "INCA32459-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2023-01-05", "completion_date": "2025-10-13", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-09-02T15:33:55.674Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05577182" }, { "nct_id": "NCT03828448", "title": "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Ublituximab", "type": "DRUG" }, { "name": "Umbralisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2019-07-10", "completion_date": "2022-05-31", "has_results": true, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-09-02T15:33:55.674Z", "location_count": 3, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • Nashville, Tennessee", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03828448" }, { "nct_id": "NCT00001676", "title": "Cyclophosphamide and Fludarabine to Treat Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glomerulonephritis", "Lupus Nephritis", "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "SQ Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "1998-01", "completion_date": "2002-11", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-02T15:33:55.674Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001676" }, { "nct_id": "NCT04697576", "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage I Cutaneous Melanoma AJCC v8", "Clinical Stage IA Cutaneous Melanoma AJCC v8", "Clinical Stage IB Cutaneous Melanoma AJCC v8", "Clinical Stage II Cutaneous Melanoma AJCC v8", "Clinical Stage IIA Cutaneous Melanoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Inactivated Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Nivolumab + Relatlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Carlo Contreras", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 36, "start_date": "2021-10-20", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-02T15:33:55.674Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697576" }, { "nct_id": "NCT00954876", "title": "Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "capecitabine and cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Translational Genomics Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-08", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2022-10-20", "last_synced_at": "2026-09-02T15:33:55.674Z", "location_count": 1, "location_summary": "Spokane, Washington", "locations": [ { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00954876" } ] }